Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Market Closed 12-12 16:00:00 EST

9.70

+0.02

+0.21%

盘后9.61

-0.09-0.93%

19:56 EST

High10.16	Low9.50	Vol497.72K
Open9.55	D1 Closing9.68	Amplitude6.82%
Mkt Cap170.26M	Tradable Cap119.18M	Total Shares17.55M
T/O4.90M	T/O Rate4.05%	Tradable Shares12.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":9.7,"timestamp":1765573200000,"preClose":9.68,"halted":0,"volume":497717,"hourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.7,"latestTime":"19:56 EST","volume":2644,"amount":25539.3417,"timestamp":1765587395001},"delay":0,"floatShares":12286700,"shares":17553037,"eps":-5.517979,"marketStatus":"Market Closed","change":0.02,"latestTime":"12-12 16:00:00 EST","open":9.55,"high":10.16,"low":9.5,"amount":4898082.768700001,"amplitude":0.068182,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.517979,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.68,"preHourTrading":{"tag":"盘前","latestPrice":9.48,"preClose":9.68,"latestTime":"09:26 EST","volume":11205,"amount":105069.52030499998,"timestamp":1765549607676},"postHourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.7,"latestTime":"19:56 EST","volume":2644,"amount":25539.3417,"timestamp":1765587395001},"volumeRatio":0.4061614638028974,"impliedVol":0.9649,"impliedVolPercentile":0.304},"requestUrl":"/m/hq/s/CRBP/wiki","defaultTab":"wiki","newsList":[{"id":"2590054194","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slides 5.7%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2590054194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590054194?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:32","pubTimestamp":1765488720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slipped 5.7% to $9.68 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 1.3% to 48,704.01 and the NASDAQ Composite Index falling 0.3% to 23,593.86.Corbus Pharmaceuticals Holdings Inc. closed 52.9% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. fell 2.2% to $6.60, Fortress Biotech Inc. remained unchanged, and Viking Therapeutics Inc. fell 0.85% to $37.21.Trading volume totaled 5.0 million, compared to the 50-day average of 422,999.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2590518435","title":"Corbus Pharmaceuticals Holdings Inc - Crb-913 Safe and Well-Tolerated Across All Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518435?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1ZSRVH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"gpt_icon":0},{"id":"2590518195","title":"Corbus Pharmaceuticals Reports Results From Phase 1a Study of Oral CB1 Inverse Agonist Crb-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518195?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1ZSRVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"gpt_icon":0},{"id":"2590484518","title":"Corbus Pharmaceuticals Holdings Inc - 12-Week Dose-Finding Study Initiated, Completion Expected Summer 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590484518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590484518?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1ZSRVH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"gpt_icon":0},{"id":"2590184365","title":"Corbus Pharmaceuticals Holdings Inc - Placebo-Adj Weight Loss of 2.9% Observed at Day 14","url":"https://stock-news.laohu8.com/highlight/detail?id=2590184365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590184365?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1ZSRVH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"gpt_icon":0},{"id":"2590755847","title":"Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590755847","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590755847?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec.  10, 2025  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203493/0/en/Corbus-Pharmaceuticals-to-Report-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-on-Thursday-December-11-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139","GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2590692013","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2590692013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590692013?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:23","pubTimestamp":1765232580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 1.27% to $10.37 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.14% to 23,545.90 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.Corbus Pharmaceuticals Holdings Inc. closed 49.56% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc.  rose 13.91% to $6.14, Fortress Biotech Inc.  rose 2.12% to $2.89, and Viking Therapeutics Inc.  fell 1.48% to $37.98.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2589810187","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slides 4.2%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810187?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:35","pubTimestamp":1764970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slipped 4.2% to $10.24 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.3% to 23,578.13 and the Dow Jones Industrial Average rising 0.2% to 47,954.99.The stock's fall snapped a two-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 50.2% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 3.7% to $5.39, Fortress Biotech Inc. rose 2.9% to $2.83, and Viking Therapeutics Inc. fell 0.05% to $38.55.Trading volume totaled 261,204, compared to the 50-day average of 411,151.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2588273940","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2588273940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588273940?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:23","pubTimestamp":1764800580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  advanced 3.79% to $10.67 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.17% to 23,454.09 and the Dow Jones Industrial Average  rising 0.86% to 47,882.90.The stock's rise snapped a three-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 48.10% below its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 7.11% to $5.27, Fortress Biotech Inc.  rose 4.67% to $2.69, and Viking Therapeutics Inc.  rose 4.52% to $35.41.Trading volume  remained 149,816 below its 50-day average volume of 406,018.Data source: Dow Jones Market Data, FactSet. Data compiled December 3, 2025.This content was created by MarketWatch, which is operated by D","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2588069546","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slides 4.4%, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2588069546","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588069546?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:34","pubTimestamp":1764711240,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slid 4.4% to $10.28 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.6% to 23,413.67 and the Dow Jones Industrial Average rising 0.4% to 47,474.46.This was the stock's third consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 50.0% short of its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its peers, as Vanda Pharmaceuticals Inc. fell 2.0% to $4.92, Fortress Biotech Inc. fell 5.5% to $2.57, and Viking Therapeutics Inc. fell 1.94% to $33.88.Trading volume totaled 199,375, compared to the 50-day average of 404,653.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2588703497","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slips 6.8%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703497?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:32","pubTimestamp":1764624720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slipped 6.8% to $10.75 on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 0.4% to 23,275.92 and Dow Jones Industrial Average falling 0.9% to 47,289.33.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 47.7% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. fell 6.3% to $5.02, Fortress Biotech Inc. fell 3.5% to $2.72, and Viking Therapeutics Inc. fell 6.14% to $34.55.Trading volume totaled 187,314, compared to the 50-day average of 406,577.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2587973030","title":"Corbus Pharmaceuticals Holdings Inc. Stock Sheds 2.9%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2587973030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587973030?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:34","pubTimestamp":1764365640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slipped 2.9% to $11.54 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.7% to 23,365.69 and the Dow Jones Industrial Average rising 0.6% to 47,716.42.Corbus Pharmaceuticals Holdings Inc. closed 43.9% below its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 1.1% to $5.36, Fortress Biotech Inc. rose 2.2% to $2.82, and Viking Therapeutics Inc. rose 1.49% to $36.81.Trading volume totaled 199,008, compared to the 50-day average of 407,493.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2586129863","title":"Corbus Pharmaceuticals Holdings Inc. Stock Advances 4.5%, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2586129863","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586129863?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:34","pubTimestamp":1764192840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. advanced 4.5% to $11.88 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 0.8% to 23,214.69 and the Dow Jones Industrial Average rising 0.7% to 47,427.12.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 42.2% short of its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 6.0% to $5.30, Fortress Biotech Inc. rose 2.6% to $2.76, and Viking Therapeutics Inc. rose 2.28% to $36.27.Trading volume totaled 129,042, compared to the 50-day average of 412,772.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2586418685","title":"Corbus Pharmaceuticals Holdings Inc. Stock Slips 4.7%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2586418685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586418685?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:34","pubTimestamp":1764020040,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. shed 4.7% to $11.44 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.7% to 22,872.01 and the Dow Jones Industrial Average rising 0.4% to 46,448.27.Corbus Pharmaceuticals Holdings Inc. closed 44.4% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 1.9% to $4.89, Fortress Biotech Inc. fell 1.5% to $2.55, and Viking Therapeutics Inc. rose 1.14% to $34.65.Trading volume totaled 300,848, compared to the 50-day average of 412,558.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2585948163","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2585948163","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585948163?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:22","pubTimestamp":1763677320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 1.10% to $11.69 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 2.15% to 22,078.05 and Dow Jones Industrial Average  falling 0.84% to 45,752.26.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 43.14% short of its 52-week high of $20.56, which the company achieved on October 20th.Despite its losses, the stock outperformed some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  fell 5.84% to $4.84, Fortress Biotech Inc.  fell 2.69% to $2.53, and Viking Therapeutics Inc.  fell 4.91% to $34.27.Trading volume  remained 130,401 below its 50-day average volume of 406,636.Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2025.This content was created by MarketWatch, which is operated by D","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2584961877","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2584961877","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584961877?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:24","pubTimestamp":1763504640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 6.76% to $12.01 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 1.21% to 22,432.85 and Dow Jones Industrial Average  falling 1.07% to 46,091.74.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 41.59% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 21.59% to $5.35, Fortress Biotech Inc.  rose 2.30% to $2.67, and Viking Therapeutics Inc.  fell 1.20% to $37.76.Trading volume  eclipsed its 50-day average volume of 389,522.Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2025.This content was created by MarketWatch, which is operated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2584677907","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2584677907","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584677907?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:21","pubTimestamp":1763418060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 1.63% to $11.25 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 0.84% to 22,708.07 and Dow Jones Industrial Average  falling 1.18% to 46,590.24.Corbus Pharmaceuticals Holdings Inc. closed 45.28% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Monday, as Vanda Pharmaceuticals Inc.  rose 1.15% to $4.40, Fortress Biotech Inc.  fell 0.38% to $2.61, and Viking Therapeutics Inc.  fell 2.28% to $38.22.Trading volume  remained 103,851 below its 50-day average volume of 389,521.Data source: Dow Jones Market Data, FactSet. Data compiled November 17, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2583510772","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510772?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:23","pubTimestamp":1763072580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 1.07% to $11.07 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 2.29% to 22,870.36 and Dow Jones Industrial Average  falling 1.65% to 47,457.22.Corbus Pharmaceuticals Holdings Inc. closed 46.16% short of its 52-week high of $20.56, which the company reached on October 20th.Despite its losses, the stock outperformed some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  fell 1.59% to $4.34, Fortress Biotech Inc.  fell 4.96% to $2.49, and Viking Therapeutics Inc.  fell 4.36% to $39.00.Trading volume  remained 104,531 below its 50-day average volume of 380,387.Data source: Dow Jones Market Data, FactSet. Data compiled November 13, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2583651830","title":"Corbus Pharmaceuticals Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651830","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583651830?lang=en_us&edition=fundamental","pubTime":"2025-11-14 01:42","pubTimestamp":1763055720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 12:42 ET (17:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2583567868","title":"RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567868?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:16","pubTimestamp":1763036168,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals yesterday and set a price target of $53.00. The company’s shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-corbus-pharmaceuticals-crbp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-corbus-pharmaceuticals-crbp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0527},{"period":"1month","weight":-0.1332},{"period":"3month","weight":0.0211},{"period":"6month","weight":0.0985},{"period":"1year","weight":-0.3568},{"period":"ytd","weight":-0.178}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.398096},{"month":2,"riseRate":0.3,"avgChangeRate":-0.057173},{"month":3,"riseRate":0.6,"avgChangeRate":0.208224},{"month":4,"riseRate":0.5,"avgChangeRate":0.045906},{"month":5,"riseRate":0.636364,"avgChangeRate":0.079186},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.065346},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.050382},{"month":8,"riseRate":0.636364,"avgChangeRate":0.095672},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.119975}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction